PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer

Ganzer, Roman and Rogenhofer, Sebastian and Walter, Bernhard and Lunz, Jens-Claudio and Schostak, Martin and Wieland, Wolf F. and Blana, Andreas (2008) PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer. EUROPEAN UROLOGY, 53 (3). pp. 547-553. ISSN 0302-2838,

Full text not available from this repository. (Request a copy)

Abstract

Objectives: To assess if prostate-specific antigen (PSA) nadir is an independent predictor of treatment failure and disease-free survival after high-intensity focussed ultrasound (HIFU) therapy for localised prostate cancer as defined by the new ASTRO criteria. Methods: One hundred three patients after HIFU treatment (Ablatherm(R), EDAP, Lyon, France) for localised prostate cancer without previous hormonal therapy were evaluated retrospectively. Patients attended regular follow-up visits every 3 mo. Treatment failure was defined by the revised ASTRO criteria (PSA >= 2 ng/ml above nadir PSA, positive biopsy, if salvage treatment was administered). Patients were divided into three PSA nadir subgroups (group 1, <= 0.2 ng/ml; group 2,0.21-1 ng/ml; group 3, >1 ng/ml). The disease-free survival rate (DFSR) was calculated by using life table methods. The log-rank test was used to compare the curves based on Kaplan-Meier models. Results: The median follow-up was 4.9 (3-8.6) yr. Mean time to PSA nadir was 6.4+/-5.1 mo. A PSA nadir of <= 0.2 ng/ml, 0.21-1 ng/ml, and >1 ng/ml was reached by 64%, 22.3%, and 13.6% of patients, respectively. Treatment failure rates during follow-up were 4.5%, 30.4%, and 100%, respectively, for the three groups (p < 0.001). The actuarial DFSRs at 5 yr were 95%, 55%, and 0%, respectively, for the 3 groups (p < 0.001). Conclusions: The PSA nadir after HIFU correlates highly significantly with treatment failure and DFSR, and can be applied in daily clinical practice. Promising oncological outcome is obtained if a PSA nadir of <= 0.2 ng/ml is reached. (C) 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Item Type: Article
Uncontrolled Keywords: RADICAL PROSTATECTOMY; RADIATION-THERAPY; MULTIINSTITUTIONAL ANALYSIS; ANTIGEN NADIR; RADIOTHERAPY; CARCINOMA; CONSENSUS; disease-free survival rate; HIFU; prostate cancer; PSA nadir; treatment failure
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Urologie
Depositing User: Dr. Gernot Deinzer
Date Deposited: 09 Nov 2020 11:19
Last Modified: 09 Nov 2020 11:19
URI: https://pred.uni-regensburg.de/id/eprint/31236

Actions (login required)

View Item View Item